Valsartan: all 252 studies that test it
Page 2 of 3. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.
- Nighttime Valsartan in Hemodialysis HypertensionStatus unknownNCT03594825Phase 4
- Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and NeprilysinStatus unknownNCT03553303Phase 4
- Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802CompletedNCT03532854Phase 1
- Glucagon-like Peptide-1 Metabolism and Acute Neprilysin InhibitionWithdrawnNCT03508739Phase 3
- Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive PatientsCompletedNCT03476616Phase 4
- Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive WomenStatus unknownNCT03432468Not applicable
- Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart FailureWithdrawnNCT03415906Phase 2
- Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II StudyWithdrawnNCT03315832Phase 2/3
- Sacubitril-valsartan Versus Usual Anti-hypertensives in LVADWithdrawnNCT03279861Phase 4
- Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVHCompletedNCT03180593Phase 4
- Comparing ARNI With ACE Inhibitor on Endothelial FunctionWithdrawnNCT03119623Phase 4
- Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2WithdrawnNCT03005184Phase 2
- Amlodipine Versus Valsartan for Improvement of Diastolic Dysfunction Associated With HypertensionCompletedNCT02973035Phase 4
- Strategies to Promote Cessation in Smokers Who Are Not Ready To QuitCompletedNCT02905656Not applicable
- The DDI Study of SP2086 and ValsartanStatus unknownNCT02817217Phase 1
- The Drug-drug Interaction of SP2086 and ValsartanCompletedNCT02815657Phase 1
- Evaluation of the Entresto Effect on Sympathic Nervous System in Patient With Heart FailureTerminatedNCT02787798Phase 4
- Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.WithdrawnNCT02662894Phase 3
- Chronopharmacology of Valsartan in Normotensive SubjectsCompletedNCT02631031Phase 1
- Physiologic Interactions Between the Adrenal- and the Parathyroid GlandsCompletedNCT02572960Phase 4
- A Bioequivalence Study of Amlodipine / Valsartan From Amlodipine/Valsartan 10/160 Tablets (Pharmacare, Palestine) and Exforge Tablets (Novartis Pharma, USA)CompletedNCT02519010Phase 1
- Bioequivalence Evaluation of Two Film-Coated Formulations of Valsartan 160 mgCompletedNCT02518451Not applicable
- A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination With Coadministration of Cilnidipine and ValsartanCompletedNCT02343250Phase 1
- Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney DiseaseStatus unknownNCT02299310Phase 4
- Bioequivalence Study of Valsartan 320mg Tablets Under Fed ConditionsCompletedNCT02197494Not applicable
- Bioequivalence Study of Valsartan 320mg Tablets Under Fasting ConditionsCompletedNCT02197442Not applicable
- Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With HypertensionCompletedNCT02145104Phase 3
- Intermittent Hypoxia 2: Cardiovascular and MetabolismTerminatedNCT02058823Phase 4
- PMS Study of Amlodipine/Valsartan for the Treatment of HypertensionCompletedNCT02058446Phase 4
- Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mgCompletedNCT01918358Phase 1
- Supramaximal Titrated Inhibition of RAAS in Dilated CardiomyopathyCompletedNCT01917149Phase 4
- Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCMCompletedNCT01912534Phase 2
- Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for HypertensionCompletedNCT01850160Phase 3
- Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses)CompletedNCT01767298Not applicable
- Pharmacokinetic Interactions of Valsartan and HydrochlorothiazideCompletedNCT01767259Not applicable
- Role of Inflammation Factors and Insulin Resistance in Major Depressive DisorderStatus unknownNCT01699490Phase 4
- New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure LoweringCompletedNCT01609959Phase 4
- Pharmacokinetic Drug Interaction Between Rosuvastatin and ValsartanCompletedNCT01609907Phase 1
- Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.CompletedNCT01541189Phase 4
- Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric PatientsCompletedNCT01447485Phase 1
- The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic SyndromeWithdrawnNCT01432106Phase 1
- Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular HypertrophyCompletedNCT01425411Phase 4
- Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 HypertensionCompletedNCT01415505Phase 3
- Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy SubjectsCompletedNCT01406431Phase 1
- Blood Pressure Lowering in Acute Stroke TrialWithdrawnNCT01400256Phase 4
- A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by MonotherapyCompletedNCT01241487Phase 4
- Drug Interaction and Safety Between Pitavastatin and Valsartan (CWP-PTV-101)CompletedNCT01232049Phase 1
- Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential HypertensionCompletedNCT01122251Phase 2
- A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Valsartan in Healthy VolunteersCompletedNCT01115972Phase 1
- Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive DiabeticsStatus unknownNCT01095822Phase 4
- FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)CompletedNCT01071122Phase 4
- Additive Effects of Pravastatin and ValsartanCompletedNCT01004237Phase 4
- Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes MellitusCompletedNCT00982358Phase 4
- Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive PatientsCompletedNCT00939588Phase 2
- The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With HypertensionCompletedNCT00921570Phase 4
- Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic StrokeStatus unknownNCT00874601Phase 4
- The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent ProteinuriaStatus unknownNCT00858299Phase 4
- Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy SubjectsCompletedNCT00839683Phase 1
- Reducing the Overall Risk Level in Patients Suffering From Metabolic SyndromeCompletedNCT00821574Phase 4
- Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)Status unknownNCT00790946Phase 4
- Regression of Fatty Heart by Valsartan TherapyWithdrawnNCT00745953Phase 4
- Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?Status unknownNCT00732966Not applicable
- Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis PatientsCompletedNCT00721773Not applicable
- Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ DamageCompletedNCT00687206Phase 4
- Blood Pressure Lowering in Acute Stroke Trial (BLAST)WithdrawnNCT00627991Not applicable
- Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in DiabetesCompletedNCT00599885Phase 4
- Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting StentCompletedNCT00589732Phase 4
- To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes MellitusCompletedNCT00550095Phase 4
- Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With HypertensionCompletedNCT00548067Phase 3
- Pathophysiological Mechanisms of Hypertensive LVH:Optimising RegressionCompletedNCT00518479Not applicable
- Preventing Microalbuminuria in Type 2 DiabetesCompletedNCT00503152Phase 3
- Preventing ESRD in Overt Nephropathy of Type 2 DiabetesCompletedNCT00494715Phase 3
- Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 MonthsCompletedNCT00487123Phase 4
- Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research（VOYAGER）StudyCompletedNCT00460213Phase 4
- Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)CompletedNCT00446524Phase 3
- Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive PatientsCompletedNCT00426478Phase 4
- Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients HypertensionCompletedNCT00425997Phase 4
- Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina PectorisTerminatedNCT00424801Not applicable
- Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.CompletedNCT00416728Phase 1
- Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.CompletedNCT00416468Phase 1
- To Compare the Blood Level of Marketed Japanese Valsartan Tablet Formulation vs Global Valsartan Tablet Formulation in Healthy VolunteersCompletedNCT00415883Phase 1
- One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With HypertensionCompletedNCT00409851Phase 3
- Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive PatientsCompletedNCT00409643Phase 3
- Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in HypertensionCompletedNCT00400777Phase 4
- Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic SyndromeCompletedNCT00394745Phase 3
- A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive PatientsCompletedNCT00392262Phase 3
- Efficacy and Safety of Valsartan and the Combination of Valsartan and SimvastatinCompletedNCT00385931Phase 3
- GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation RecurrenceCompletedNCT00376272Phase 3
- Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus FelodipineCompletedNCT00367939Phase 3
- Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus HydrochlorothiazideCompletedNCT00360178Phase 3
- Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II HypertensionCompletedNCT00353912Phase 3
- Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current MonotherapyCompletedNCT00351130Phase 4
- Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II HypertensionCompletedNCT00350168Phase 3
- The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)TerminatedNCT00343499Phase 4
- Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)CompletedNCT00338936Phase 3
- Comparative Study of Valsartan and Amlodipine Versus Amlodipine Alone in HypertensionCompletedNCT00333489Phase 4
- 8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe HypertensionCompletedNCT00327587Phase 3
- A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on MonotherapyCompletedNCT00327145Phase 3
- A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)CompletedNCT00311740Phase 3
- Effects of Sodium Intake on (PK/PD) Relationship of a Single Dose of a Renin Angiotensin System-BlockerCompletedNCT00310778Phase 1